mt-304
HER2-Expressing Solid Tumors
Myeloid TherapeuticsPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the HER2-Expressing Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Myeloid Therapeutics | Phase 1 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →